In preclinical models, sFLT3L alone or in combination with radiotherapy, CD40 agonists, or TLR3 agonists (e.g., poly(I:C)) improved tumor control, enhanced CD8+ T‐cell cross‐priming, and in some cases triggered abscopal effects. The gene discussed is CD8A; the disease is neoplasm.